Operator

Good day, ladies and gentlemen. Welcome to Relay Therapeutics Vascular Anomalies Update Call. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Mr. Pete Rahmer, Chief Corporate Development Officer at Relay Therapeutics. Sir, you may begin.

Peter Rahmer
Chief Corporate Development Officer

Thank you, operator, and good morning, everyone. Thanks for joining us. We are very excited to share our initial vascular anomalies data with you today. You can access the press release from today. The slides we are reviewing and a replay of this call by going to the Investor Relations section of our website.

As a reminder, during this call, we will make certain statements that are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including expressed or implied statements regarding our strategy, business plans and objectives, and expected therapeutic and clinical benefits of our product candidates, potential of our platform and our product animates progress, timing and execution of our clinical trials. Such forward-looking statements are not guarantees of future performance, and therefore, you should not put undue reliance upon them. These statements are